Disclaimer
For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
Insight into the different treatment options to reduce the risk of stroke in AF patients
Treatments to Reduce the Risk of Stroke in AF
Oral Anticoagulants
The most common treatment for managing AF-related stroke risk is the use of anticoagulants, such as warfarin (Coumadin®) and novel oral anticoagulants (NOACs).
Warfarin and NOACs effectively reduce the risk of cardioembolic stroke, however they are not well tolerated by some patients and carry a risk for bleeding complications.
The limits of oral anticoagulants include:
- Risk of bleeding
- High rate of discontinuation (at 2 years, 50% of patients on VKA and 30% on NOAC treatment)1
- Interactions with certain foods and medications (warfarin)
- Frequent blood tests and dose adjustment (warfarin)
WATCHMAN FLX implant procedure
The WATCHMAN FLX device offers a breakthrough approach to reduce the risk of stroke. Most blood clots in people with AF develop in the left atrial appendage (LAA).
WATCHMAN FLX acts as a barrier to keep these blood clots from escaping the LAA, going into the bloodstream, blocking a blood vessel, and causing a stroke.
REFERENCES
1. Martinez et al. Thromb Haemost 2015;114: In press.
CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.